Chemistry:Rosmantuzumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | RSPO3 |
| Clinical data | |
| Other names | OMP-131R10 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6456H9954N1714O2048S46 |
| Molar mass | 145825.36 g·mol−1 |
Rosmantuzumab (INN;[1] development code OMP-131R10) is a humanized monoclonal antibody designed for the treatment of cancer.[2][3][4]
This drug was developed by OncoMed Pharmaceuticals.[5]
References
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115". WHO Drug Information 30 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf.
- ↑ "Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review)". Int. J. Mol. Med. 42 (2): 713–725. August 2018. doi:10.3892/ijmm.2018.3689. PMID 29786110.
- ↑ "Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)". Int. J. Oncol. 51 (5): 1357–1369. November 2017. doi:10.3892/ijo.2017.4129. PMID 29048660.
- ↑ "Molecular genetics and targeted therapy of WNT-related human diseases (Review)". Int. J. Mol. Med. 40 (3): 587–606. September 2017. doi:10.3892/ijmm.2017.3071. PMID 28731148.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Rosmantuzumab, American Medical Association.
 |  |
